James Adams
Chief Technical Officer TR1X Bio
Seminars
Thursday 25th March 2027
Advancing Off-the-Shelf Immune Tolerance with Allogeneic TR1 Cell Therapies
1:30 pm
- Showcasing how a non-gene-edited allogeneic TR1 platform is simplifying manufacturing and broadening access to immune tolerance therapies
- Presenting safety and translational insights challenging historical concerns around allogeneic regulatory cell therapies and GvHD risk
- Evaluating opportunities for scalable off-the-shelf TR1 therapies to overcome cost, manufacturing, and accessibility barriers across autoimmune disease indications